VRSN
53
-4
NKE
36
6
TJX
64
2
PYPL
54
2
APD
59
2
WU
32
2
AA
48
-12
DE
63
3
BWA
48
2
MCHP
41
4
ADT
53
3
WM
79
3
LB
63
22
LMT
34
2
BA
54
5
HCP
66
8
CFG
70
6
CSCO
67
4
XRX
44
3
MAT
46
12
VRSN
53
-4
NKE
36
6
TJX
64
2
PYPL
54
2
APD
59
2
WU
32
2
AA
48
-12
DE
63
3
BWA
48
2
MCHP
41
4
ADT
53
3
WM
79
3
LB
63
22
LMT
34
2
BA
54
5
HCP
66
8
CFG
70
6
CSCO
67
4
XRX
44
3
MAT
46
12
Financhill
Back

Dermata Therapeutics 10K Form

Sell
20

DRMA
Dermata Therapeutics

Last Price:
1.11
Seasonality Move:
-52.03%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive DRMA News And Ratings

See the #1 stock for the next 7 days that we like better than DRMA

DRMA Financial Statistics

Sales & Book Value

Annual Sales: --
Cash Flow: $-3.42M
Price / Cash Flow: 0
Annual Sales: $2.83
Price / Book: 0.49

Profitability

EPS (TTM): -21.41320
Net Income (TTM): $-11.27M
Gross Margin: --
Return on Equity: 0%
Return on Assets: 0%

Dermata Therapeutics Earnings Forecast

Key Dermata Therapeutics Financial Ratios

  • The Interest Expense is 0.62% of Operating Income.
  • Per Share Earnings over the last 5 years have been positive in 3 years.

Dermata Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: DRMA
Website: dermatarx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

DRMA Technical Analysis vs Fundamental Analysis

Sell
20
Dermata Therapeutics (DRMA) is a Sell

Is Dermata Therapeutics a Buy or a Sell?